Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00804934
Recruitment Status : Completed
First Posted : December 9, 2008
Last Update Posted : May 28, 2012
Information provided by (Responsible Party):
Retina Institute of Hawaii

Brief Summary:
The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

Condition or disease Intervention/treatment
Wet AMD Drug: Lucentis

Detailed Description:
To determine mean change in visual acuity at 6 and 12 months

Study Type : Observational
Actual Enrollment : 100 participants
Official Title: Phase II Study Intravitreally Admininstered Ranibizumab in 50 Subjects With AMD Having Received at Least 3 Doses of Intermittent Anti-VEGF Therapy in the Preceding 18 Months
Study Start Date : February 2008
Actual Primary Completion Date : February 2008
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab
U.S. FDA Resources

Group/Cohort Intervention/treatment
0 Drug: Lucentis
0.5mg Lucentis every four months

Primary Outcome Measures :
  1. Mean change in visual acuity at 6 and 12 months [ Time Frame: one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age greater then and equal 50 years
  • Patients with active neovascular AMD
  • Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months
  • If the patient has bilateral disease and qualifies for the study, both eyes may be included

Exclusion Criteria:

  • Subjects who meet any of the following criteria will be excluded from this study:
  • Pregnancy or lactation
  • Premenopausal women not using adequate contraception.
  • Participation in another simultaneous medical investigation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00804934

United States, Hawaii
Retina Institute of Hawaii
Honolulu, Hawaii, United States, 96815
Sponsors and Collaborators
Retina Institute of Hawaii
Study Chair: Debra L Shimabukuro, RN Retina Institute of Hawaii

Responsible Party: Retina Institute of Hawaii Identifier: NCT00804934     History of Changes
Other Study ID Numbers: F4421S
First Posted: December 9, 2008    Key Record Dates
Last Update Posted: May 28, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents